Myasthenia Gravis Clinical Trial
Official title:
A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Anterior Mediastinal Disease
Verified date | October 2023 |
Source | Chang Gung Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Endpoints (Outcome measures): 1. Primary endpoint: Incidence of conversion rate during surgery - The primary performance endpoint will be assessed as the ability to successfully complete the planned mediastinal procedure with da Vinci SP System, with no conversion to open surgery, video-assisted thoracoscopic surgery (VATS), multi-port robotic surgery or approach requiring undocking of the da Vinci SP Surgical System in order to complete the planned procedure using the alternate approach. Use of additional assistant port(s) is not considered a conversion 2. Secondary endpoints: Incidence of treatment related adverse events - The safety endpoint will be assessed as the incidence of all intra-operative and post-operative adverse events that occur through the 30-day follow up period
Status | Active, not recruiting |
Enrollment | 15 |
Est. completion date | April 11, 2024 |
Est. primary completion date | April 11, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion criteria 1. Age >20 and <75 years-old 2. Willing and able to provide informed consent 3. ASA= 3 4. The subject fulfills one or both of the following criteria: - Diagnosis of myasthenia gravis - Masaoka stage I or II thymoma; thymic mass = 5 cm diameter 5. Class I-IV Myasthenia gravis according to the Myasthenia Gravis Foundation of America Scientific Session (MGFA) Exclusion criteria. Myasthenia gravis or thymoma patients with 1. Congestive heart failure (NHYA > II) 2. Arrhythmia required medication control 3. Subjects with a known bleeding or clotting disorder 4. Subjects actively receiving therapeutic dose anticoagulation or anti-platelet medications at the time of operation 5. Subjects under immunomodulatory within 30 days prior to the planned surgery 6. Previous ipsilateral thoracic surgery or sternotomy 7. Uncontrolled illness 6 months prior to planned surgical procedure including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 8. Previous neoadjuvant medical and/or radiation therapy 9. Subject has a contraindication for general anesthesia or surgery 10. Uncontrolled myasthenia gravis symptoms at the time of scheduled surgery 11. Confirmed thymic carcinoma 12. Patients who are not suitable for performing endoscopic surgery. 13. Myasthenia gravis patients with positive serum MuSK antibody. - |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Memeorial Hospital, Linkou Medical Center | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of conversion rate | The primary performance endpoint will be assessed as the ability to successfully complete the planned procedure with da Vinci SP System, with no conversion to thoracoscopic, multi-port robotic, or open surgery. | During Surgery | |
Secondary | Incidence of Treatment-Emergent Adverse Events | The safety endpoint will be assessed as the incidence of all intra-operative and post-operative adverse events that occur through the 30-day follow up period. Rceord the Incidence of Treatment-Emergent Adverse Events in our recording form | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|